Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females

NCT04824131 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Oral cabotegravir (CAB)
DRUG: CAB LA
DRUG: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]